Kadmon is a biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology, and genetic diseases.
Revenue (Q1, 2018)
Gross profit (Q1, 2018)
Gross profit margin (Q1, 2018), %
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (22-Jun-2018)
Closing share price (22-Jun-2018)